- In April 2023, Teva Pharmaceutical Industries Ltd. expanded its cardiovascular portfolio by launching a new line of metoprolol tartrate tablets across key emerging markets in Latin America and Southeast Asia. This strategic move aims to enhance access to affordable cardiovascular care by offering high-quality generics in regions experiencing rising hypertension rates. Teva’s expansion underscores its commitment to addressing the global burden of heart disease through accessible treatment options
- In March 2023, Aurobindo Pharma Ltd. received regulatory approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for metoprolol tartrate tablets USP. The approval paves the way for the company to strengthen its presence in the North American generic cardiovascular drug market. Aurobindo’s growing portfolio of approved cardiovascular generics reinforces its strategy to deliver cost-effective therapies to patients in need
- In February 2023, Lupin Limited, a global pharmaceutical company headquartered in India, launched its metoprolol tartrate tablets in the U.K. under the NHS drug formulary. The launch supports NHS objectives of ensuring access to affordable essential medications and positions Lupin as a key contributor to the British generic cardiovascular therapeutics market
- In January 2023, Torrent Pharmaceuticals Ltd. entered into a partnership with a leading hospital group in the Middle East to supply metoprolol tartrate and other essential cardiovascular drugs for their institutional needs. This collaboration is part of a broader initiative to improve drug supply chains in the region and promote access to WHO-listed essential medicines
- In January 2023, Zydus Lifesciences Ltd. announced the successful completion of bioequivalence studies for its extended-release formulation of metoprolol tartrate. This development sets the stage for regulatory filings across regulated markets including the U.S. and Europe. The move reflects Zydus’s focus on innovation in generic formulation technologies, aiming to improve patient compliance through more convenient dosing options
